viloxazine ER Qelbree
Selected indexed studies
- Viloxazine ER (Qelbree) for ADHD. (Med Lett Drugs Ther, 2021) [PMID:34181631]
- Viloxazine ER (Qelbree(®)): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder. (J Psychosoc Nurs Ment Health Serv, 2022) [PMID:35858173]
- Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. (CNS Drugs, 2023) [PMID:37166701]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Recent advances in pharmacological management of attention-deficit/hyperactivity disorder: moving beyond stimulants. (2024) pubmed
- Pediatric attention deficit hyperactivity disorder (ADHD): 2022 updates on pharmacological management. (2023) pubmed
- Viloxazine ER (Qelbree) for ADHD. (2021) pubmed
- Nonstimulant Medications for Attention-Deficit/Hyperactivity Disorder (ADHD) in Adults: Systematic Review and Meta-analysis. (2023) pubmed
- Viloxazine ER (Qelbree(®)): A New Non-Stimulant Option in the Treatment of Pediatric Attention-Deficit/Hyperactivity Disorder. (2022) pubmed
- Adult Attention-Deficit/Hyperactivity Disorder: a Narrative Review of Biological Mechanisms, Treatments, and Outcomes. (2023) pubmed
- A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. (2022) pubmed
- Nonstimulant Medications for Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. (2025) pubmed
- Impact of Viloxazine Extended-Release Capsules (Qelbree(®)) on Select Cytochrome P450 Enzyme Activity and Evaluation of CYP2D6 Genetic Polymorphisms on Viloxazine Pharmacokinetics. (2024) pubmed
- An Open-Label Extension Study Assessing the Long-Term Safety and Efficacy of Viloxazine Extended-Release Capsules in Adults with Attention-Deficit/Hyperactivity Disorder. (2024) pubmed